500,000 Shares in Black Diamond Therapeutics, Inc. $BDTX Purchased by AWM Investment Company Inc.

Key Points

• AWM Investment Company Inc. has acquired a stake in Black Diamond Therapeutics, purchasing 500,000 shares valued at approximately $775,000, representing 0.88% ownership.
• The stock of Black Diamond Therapeutics (NASDAQ: BDTX) has shown recent trading activity with a market cap of $159.43 million and has a 1-year price range of $1.20 to $6.33.
• Analysts hold a generally positive outlook on Black Diamond Therapeutics, with an average rating of "Buy" and a consensus price target of $12.40.

AWM Investment Company Inc. acquired a new stake in shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 500,000 shares of the company's stock, valued at approximately $775,000. AWM Investment Company Inc. owned approximately 0.88% of Black Diamond Therapeutics as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. D. E. Shaw & Co. Inc. bought a new stake in Black Diamond Therapeutics in the 4th quarter valued at about $37,000. Barclays PLC grew its position in Black Diamond Therapeutics by 10.7% in the fourth quarter. Barclays PLC now owns 86,545 shares of the company's stock worth $186,000 after acquiring an additional 8,394 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in Black Diamond Therapeutics during the fourth quarter valued at about $53,000. JPMorgan Chase & Co. raised its stake in shares of Black Diamond Therapeutics by 429.6% during the fourth quarter. JPMorgan Chase & Co. now owns 18,929 shares of the company's stock valued at $41,000 after acquiring an additional 15,355 shares during the last quarter. Finally, Millennium Management LLC raised its stake in shares of Black Diamond Therapeutics by 503.0% during the fourth quarter. Millennium Management LLC now owns 558,076 shares of the company's stock valued at $1,194,000 after acquiring an additional 465,531 shares during the last quarter. 95.47% of the stock is owned by institutional investors.

Black Diamond Therapeutics Trading Down 1.2%

Black Diamond Therapeutics stock traded down $0.04 during midday trading on Monday, hitting $2.91. 356,501 shares of the stock were exchanged, compared to its average volume of 1,884,674. Black Diamond Therapeutics, Inc. has a fifty-two week low of $1.20 and a fifty-two week high of $6.33. The stock has a market capitalization of $165.41 million, a price-to-earnings ratio of 12.63 and a beta of 2.93. The stock's 50-day simple moving average is $2.78 and its 200 day simple moving average is $2.19.

Black Diamond Therapeutics (NASDAQ:BDTX - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.19) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.06. Equities analysts anticipate that Black Diamond Therapeutics, Inc. will post -1.3 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on BDTX shares. HC Wainwright decreased their target price on shares of Black Diamond Therapeutics from $12.00 to $10.00 and set a "buy" rating for the company in a research note on Monday, August 11th. Wall Street Zen downgraded shares of Black Diamond Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. Zacks Research upgraded shares of Black Diamond Therapeutics to a "strong-buy" rating in a report on Monday, August 11th. Guggenheim initiated coverage on shares of Black Diamond Therapeutics in a report on Wednesday. They set a "buy" rating and a $8.00 price target on the stock. Finally, Raymond James Financial raised shares of Black Diamond Therapeutics to an "outperform" rating and set a $11.00 price objective for the company in a research report on Tuesday, July 1st. One investment analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $11.67.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.